Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705)
Launched by CSL BEHRING · Nov 15, 2019
Trial Information
Current as of August 11, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial, called BMT CTN 1705, is looking at a new treatment approach for patients experiencing a condition known as Graft Versus Host Disease (GVHD) after receiving a stem cell transplant. GVHD can happen when the donor's immune cells attack the recipient's body. The study will compare two treatment options: a combination of a medication called AAT and corticosteroids (which are anti-inflammatory drugs) versus using corticosteroids alone. The goal is to see if adding AAT helps patients with high-risk acute GVHD feel better more quickly.
To participate in this trial, patients need to be at least 12 years old and have just been diagnosed with acute GVHD after their stem cell transplant. It’s important that they haven't received certain prior treatments for GVHD or have ongoing cancers. If patients join the study, they will receive either the new treatment combination or the standard corticosteroids and be monitored closely by the research team. This study is currently active, but it is not recruiting new participants at this time. If you or a loved one are dealing with GVHD, this trial represents an important effort to find better treatment options.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 12 years of age or older
- • Initial presentation of acute GVHD after allogeneic hematopoietic cell transplantation for any indication
- • Any graft or donor source or conditioning intensity
- • Clinical diagnosis of acute GVHD requiring systemic therapy with corticosteroids
- Exclusion Criteria:
- • Prior exogenous AAT exposure for GVHD prophylaxis
- • Relapsed, progressing, or persistent malignancy
- • de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment
- • Receiving other drugs for the treatment of GVHD
- • Receiving systemic CS for any indication within 7 days before the onset of acute GVHD
About Csl Behring
CSL Behring is a global biotechnology leader focused on developing innovative therapies for patients with serious and rare diseases. As a subsidiary of CSL Limited, the company specializes in the research, development, and manufacture of life-saving biotherapies derived from human plasma. With a strong commitment to scientific excellence and patient care, CSL Behring conducts rigorous clinical trials to advance its portfolio of immunoglobulins, clotting factors, and other biopharmaceuticals. The organization aims to enhance the quality of life for patients worldwide while maintaining the highest standards of safety and efficacy in its products.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minneapolis, Minnesota, United States
New York, New York, United States
Milwaukee, Wisconsin, United States
Stanford, California, United States
Nashville, Tennessee, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Tampa, Florida, United States
Baltimore, Maryland, United States
Cleveland, Ohio, United States
Saint Louis, Missouri, United States
Madison, Wisconsin, United States
Houston, Texas, United States
Atlanta, Georgia, United States
Detroit, Michigan, United States
Gainesville, Florida, United States
New York, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
Westwood, Kansas, United States
Ann Arbor, Michigan, United States
Columbus, Ohio, United States
Houston, Texas, United States
Richmond, Virginia, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Study Director
Study Director
CSL Behring
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials